CION Ameerpet
A yolk sac tumour — older reports call it an endodermal sinus tumour — is a malignant germ cell tumour of the ovary that mostly affects girls and women in their teens and twenties. It grows fast, which is frightening to watch and is also the reason it is usually still confined to one ovary when it is found. It responds to chemotherapy exceptionally well, the uterus and the opposite ovary are left in place in almost every case, and most young women resume periods afterwards.
A yolk sac tumour is a malignant tumour that arises from the ovary's germ cells — the primordial cells that would otherwise have become eggs — and then grows in a pattern that copies the yolk sac, the structure that nourishes a very early embryo. That is where the name comes from, and it is also why the tumour produces alpha-fetoprotein (AFP), a protein the yolk sac makes. Older reports call the same tumour an endodermal sinus tumour; the two names describe one disease. It is the second commonest malignant ovarian germ cell tumour, after dysgerminoma.
It is worth knowing what you are reading when you search. Type “yolk sac tumour ovary” into a search box and you will get a mix of paediatric oncology papers, testicular tumour research and general ovarian cancer pages — and that last category, including our own complete guide to ovarian cancer, is mostly describing epithelial ovarian cancer in women over 50. Different cell of origin, different age group, different treatment, and a very different outlook. BRCA, family history and reproductive history, which dominate the conversation about epithelial disease, have no established link with this tumour at all.
Now the part that matters on the day of diagnosis. This tumour grows quickly, and that speed is usually what brings a young woman to hospital — symptoms measured in weeks, not months, sometimes with sudden pain because the ovary has twisted. Fast growth sounds like bad news and mostly is not: it is the reason most of these tumours are still confined to one ovary when they are found. It is also one of the cancers that combination chemotherapy transformed. Treatment is intensive but short, the uterus and the opposite ovary stay where they are in almost every case, and most young women resume normal periods afterwards.
A different cell of origin, a different age group and a different plan. Most general ovarian cancer information is not describing this tumour.
One disease, two names. If the pathology report uses the older term, nothing about the diagnosis or the treatment changes.
The tumour makes alpha-fetoprotein, so a blood test can follow it almost in real time — during treatment and for years afterwards.
Yolk sac tumour is the second commonest malignant germ cell tumour of the ovary after dysgerminoma, and its behaviour is defined by two features. It secretes alpha-fetoprotein, raised in the great majority of cases, which gives clinicians a blood test that tracks the tumour almost in real time. And under the microscope it forms Schiller-Duval bodies — a distinctive structure resembling a primitive glomerulus — which, with AFP immunostaining, settles the diagnosis. It is also one of the clearest illustrations in oncology of what combination chemotherapy changed: in the era before platinum-based regimens an ovarian yolk sac tumour was very seldom survived, and it is now usually curable, most often without sacrificing fertility. Source: WHO Classification of Tumours — Female Genital Tumours (5th ed.); NCCN Guidelines for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer.
These two account for most malignant ovarian germ cell tumours, and families often end up reading about the wrong one. The differences below are the ones that change what happens next.
| What differs | Yolk sac tumour | Dysgerminoma |
|---|---|---|
| Marker that tracks it | AFP, raised in the great majority; beta-hCG and LDH usually unremarkable | LDH characteristically raised; AFP normal in a pure dysgerminoma |
| Typical age | Children, adolescents and women in their early twenties | Adolescents and women in their twenties |
| Speed of growth | Fast — symptoms are often measured in weeks, and torsion or rupture is not rare | Fast, but the onset is usually less abrupt |
| The opposite ovary | Almost always normal; involvement of both ovaries is rare | Involved in a meaningful minority, so it is inspected at surgery |
| After surgery for early-stage disease | Chemotherapy follows in almost every case | Selected fully staged stage IA disease can be watched instead |
| Radiotherapy | No established role — this tumour is not radiosensitive | Historically very radiosensitive, though chemotherapy has replaced it |
| What follow-up watches | AFP, which falls at a predictable rate once the tumour is out | LDH and periodic imaging |
*The most useful line here is the first one. A raised AFP alongside dysgerminoma-like histology means a mixed germ cell tumour containing a yolk sac component, and the tumour is then treated according to that component rather than the dysgerminoma part. What each marker means is set out in tumour markers for germ cell tumours.
The sequence moves faster than it does for most cancers, because the tumour does. Most of it happens within days to a couple of weeks, and most of it happens before any decision about chemotherapy.
Three germ cell markers are checked — AFP, beta-hCG and LDH — along with a pregnancy test. AFP is the important one here: it is raised in the great majority of yolk sac tumours, and the level taken before surgery is what makes the fall afterwards interpretable. If that baseline is missed, a genuinely useful measurement is lost and cannot be recovered.
AFP is not specific to cancer, which is why it is read alongside the scan and the pathology rather than on its own. It is physiologically high in babies and falls over the first months of life, it rises in pregnancy, and it goes up in several liver conditions. Beta-hCG and LDH are checked mainly to flag a mixed germ cell tumour. There is more detail on the germ cell tumour markers page.
Pelvic ultrasound comes first and often gives the strongest clue: a large, solid, rapidly grown mass in a young patient. A CT scan of the chest, abdomen and pelvis then establishes whether anything has spread beyond the ovary. MRI is sometimes preferred in a child or a young woman where radiation dose is a consideration.
What is generally not done is a needle biopsy through the abdominal wall. Where a germ cell tumour is suspected, the mass is removed whole, because puncturing or spilling it can seed tumour cells into the abdomen and raise the stage. If the team seems to be skipping a step, this is the reason — the diagnosis is made on the complete specimen after it comes out.
The report should state whether this is a pure yolk sac tumour or a mixed germ cell tumour, and if mixed, which components are present and in what proportion. Schiller-Duval bodies are the characteristic finding, and AFP immunostaining supports it, though not every tumour shows the classic pattern — several architectural variants exist and they can be difficult to recognise in a centre that rarely sees one.
The report should also describe whether the capsule of the ovary was intact, whether tumour was present on its surface, and what the peritoneal washings showed, because all three feed the stage. If any of it is unclear, ask for it to be explained rather than working from the summary line. A second opinion on the slides is reasonable where the diagnosis was made somewhere that sees few germ cell tumours.
AFP clears from the blood at a known rate once the source is gone — its half-life is roughly five to seven days — so the level is measured repeatedly and plotted against that expected decline. A fall that follows the curve is reassuring. A fall that stalls, plateaus or reverses suggests tumour is still present somewhere, and that finding often carries more weight than a scan at the same point in time.
This is also why AFP is the backbone of follow-up. A rise after treatment can flag recurrence before anything is visible on imaging or felt on examination, which is precisely when it is most treatable. One caution worth knowing: AFP rises in pregnancy, so a later pregnancy needs to be mentioned before anyone reads too much into a number.
FIGO staging is the same system used for all ovarian cancers: stage I is confined to the ovary or ovaries, stage II has spread within the pelvis, stage III involves the abdominal cavity or its lymph nodes, and stage IV is spread further afield. Most yolk sac tumours are stage I at diagnosis, and almost all are confined to one side.
The stage matters, but it does not carry the weight here that it carries in epithelial ovarian cancer. Because this tumour is so chemosensitive, advanced disease is still usually treated with the intention of curing it, and fertility-sparing surgery is still usually appropriate. In practice the stage influences how much chemotherapy is given rather than whether cure is the aim. What treatment involves is set out on our ovarian cancer treatment in Hyderabad page.
Most of what a family needs in the first week is not another test. It is forty-five minutes with someone who can say plainly what this tumour is, what the AFP number means, what surgery is involved, how long chemotherapy lasts, and what happens to fertility.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the scan, the pathology report and any AFP results — most of the questions that actually matter can be answered in one sitting.
Treatment rests on one governing fact: this tumour responds so well to chemotherapy that the surgery does not have to be extensive. Almost everything below follows from that.
Standard surgery removes the involved ovary and its fallopian tube and leaves the uterus and the opposite ovary in place. Because these tumours are almost always one-sided, a normal-looking opposite ovary is not removed and usually not biopsied. This is not a concession made for fertility at the cost of outcome; it is standard management. Surgery of this kind is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — CION arranges it with the surgical team rather than performing it in-house, and we would rather say so at the start than have you discover it at admission.
Peritoneal washings are taken, the abdominal surfaces and diaphragm are inspected, and any abnormal lymph nodes are sampled. Careful handling matters more than usual with this tumour: it is soft, often large, and rupturing it during removal raises the stage. Incomplete staging is the commonest reason a young woman ends up back in theatre, or receiving treatment she might not have needed.
This is the main point of difference from dysgerminoma, where selected early-stage disease can simply be watched. For a yolk sac tumour, a short course of platinum-based combination chemotherapy — usually three or four cycles — follows surgery in almost all cases, including most fully resected stage I disease, because the risk of relapse without it is real and relapse is harder to treat than the original tumour. Close surveillance after complete removal is used in selected children under paediatric protocols, and that is a specialist decision rather than a default. Chemotherapy is delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh.
AFP is measured before each cycle and its fall compared with the expected decline. A marker that keeps falling does more to confirm that treatment is working than any single scan. A marker that plateaus or rises prompts a change of plan rather than another cycle of the same thing — exactly the sort of decision worth having reviewed by a tumour board rather than one doctor.
Most young women resume normal periods after treatment and are able to conceive naturally, because the uterus and one ovary have been kept and the chemotherapy course is short. That is the usual outcome, not the optimistic one. Even so, the conversation belongs before treatment starts rather than after it ends: fertility preservation is worth discussing where a longer course is planned, where the remaining ovary is not normal, or simply where you want the additional security. Ask for it explicitly if nobody raises it.
Relapse, when it happens, happens early — usually within the first year — so follow-up is intensive at the start and eases off afterwards. It combines examination, AFP and periodic imaging. Later on it shifts towards what matters to a woman in her twenties and thirties: ovarian function, periods, planning a pregnancy, and the long-term effects of chemotherapy. The wider picture for this family of tumours is in our guide to germ cell ovarian tumours in young women.
Where you are treated counts for more than usual with an uncommon tumour in a young patient. The decisions that go wrong tend to be the early ones — a mass punctured or spilled rather than removed intact, a pre-operative AFP never taken, staging left incomplete, or chemotherapy started before the pathology has been reviewed properly.
The person reading this is often a parent, and sometimes a woman in her late teens or twenties whose year has been interrupted by something that appeared in the space of a month. What is needed first is rarely another test. It is someone with the time to explain what this tumour is, what the AFP number means, what the surgery involves, how long chemotherapy lasts and what it does to fertility — in that order, and without hedging.
Your first consultation at CION is free and runs to about 45 minutes. Bring the scan, the pathology report and any AFP results, including the pre-operative level if one was taken. Every case that raises a question goes to a tumour board rather than being settled by one doctor, which matters more with an uncommon tumour than with a common one, precisely because the early decisions are the consequential ones.
We are equally plain about who does what. Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with nutrition support, survivorship care and long-term follow-up, and genetic counselling where the picture calls for it. Fertility-sparing surgery and surgical staging are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. CION arranges that surgery and stays involved through it; we do not perform it ourselves.
One word on the numbers, because you will have looked them up. CION publishes its own one-year survival for ovarian cancer alongside the national figure: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. Both are one-year figures across an entire treated population — not cure rates, and not predictions for any individual. Both are also dominated by epithelial ovarian cancer in women over 50, a different disease with a different natural history. Published ovarian cancer survival statistics understate the outlook for a yolk sac tumour considerably, and the oldest of them were compiled before modern chemotherapy existed. The figures worth discussing are the ones your oncologist can give you for this tumour, at this stage.
Free, unhurried, and long enough to cover surgery, chemotherapy, AFP and fertility in one sitting rather than three visits.
Multidisciplinary review, which counts for more with a rare tumour where the first decisions are the ones that stick.
Delivered by CION across Telangana and Andhra Pradesh, so cycles and follow-up can happen near where you live.
Fertility-sparing and staging surgery is arranged with specialist gynaecologic-oncology partner centres and may be billed there.
*One-year survival rates across all ovarian cancer types and stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Both are dominated by epithelial ovarian cancer and describe groups rather than individuals — discuss the outlook for a yolk sac tumour specifically with your treating oncologist.
It is a malignant germ cell tumour — a cancer arising from the primordial cells that would otherwise have become eggs, rather than from the surface lining where the common ovarian cancers begin. It grows in a pattern that copies the yolk sac of a very early embryo, which is where the name comes from and why the tumour produces alpha-fetoprotein (AFP). Older reports call it an endodermal sinus tumour; it is the same disease. It is the second commonest malignant ovarian germ cell tumour after dysgerminoma, occurs mainly in children, teenagers and women in their early twenties, and usually presents as a rapidly enlarging pelvic mass with symptoms measured in weeks rather than months.
AFP is raised in the great majority of ovarian yolk sac tumours, which gives doctors something very few cancers offer: a blood test that reflects what the tumour is doing almost in real time. A level taken before surgery provides the baseline. Afterwards AFP clears at a known rate — its half-life is roughly five to seven days — so repeated measurements can be plotted against that expected decline. A fall that follows the curve is reassuring; one that stalls or reverses suggests tumour is still present, sometimes before any scan shows it. The same logic makes AFP the backbone of follow-up, since a rise can flag recurrence early. AFP is not specific to cancer, though: it is high in infants, rises in pregnancy and goes up in several liver conditions, so it is always read alongside imaging and pathology.
In almost all cases, yes — and this is the main way a yolk sac tumour differs from a dysgerminoma, where selected fully staged stage IA disease can be watched instead. For a yolk sac tumour, a short course of platinum-based combination chemotherapy, usually three or four cycles, follows surgery even when the tumour appears completely removed, because the risk of relapse without it is real and a relapse is harder to treat than the original disease. Close surveillance after complete removal is used in selected children under paediatric protocols, but that is a specialist decision made case by case, not a general alternative. If observation is being offered to you, ask specifically why your case qualifies.
In most cases, yes. Standard surgery removes only the affected ovary and its tube and leaves the uterus and the opposite ovary in place, and because these tumours are almost always one-sided, a normal opposite ovary is not removed. Chemotherapy is a short course, and most young women resume normal periods afterwards and conceive naturally. That is the usual outcome rather than the hopeful one. Fertility preservation is still worth discussing before treatment starts — particularly if a longer course is planned or the remaining ovary is not normal — and the conversation belongs before the first cycle, not after the last. If nobody raises it, raise it yourself.
Usually not. Fast growth is what this tumour does, and it is generally the reason it is found early rather than a sign that it has travelled: most are still confined to one ovary at diagnosis. The speed is why symptoms appear over weeks, and why sudden pain from a twisted ovary is a common way in. Staging at surgery, together with a CT scan of the chest, abdomen and pelvis, is what actually answers the question, and the pre-operative AFP level adds to the picture. Even where disease has spread beyond the ovary, this tumour is so sensitive to chemotherapy that treatment is still given with the intention of curing it — the stage tends to influence how much treatment is needed rather than what the aim is.
The first consultation is free and runs to about 45 minutes — bring the scan, the pathology report and any AFP results, since whether this is a pure yolk sac tumour or a mixed germ cell tumour changes the plan. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, alongside nutrition support, survivorship care and long-term follow-up, and genetic counselling where the picture calls for it. Fertility-sparing surgery and surgical staging are coordinated with specialist gynaecologic-oncology partner centres and may be billed there; CION arranges the surgery and stays involved through it rather than performing it in-house. Every case is reviewed at a tumour board, which counts for more with a rare tumour where the early decisions carry the most weight.